ADE:XETRBitcoin Group SE Analysis
Data as of 2026-05-17 - not real-time
$29.88
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Adeia Inc. (ADE) is trading at $29.88, which sits just below its 20‑day SMA of $30.49 but comfortably above the 50‑day SMA of $27.00, indicating a short‑term pullback within a broader uptrend. The 200‑day SMA at $18.84 underscores a strong long‑term bullish bias. Technical momentum is mixed: the RSI of 52 suggests neutral pressure, while the MACD histogram is negative and the signal line is flagged bearish, hinting at potential near‑term downside. Volume has been increasing, supporting the price move, but the 30‑day volatility of ≈75% signals wide price swings. The stock’s beta of ~2.07 points to heightened sensitivity to market moves, and a max drawdown of ‑34.8% reflects historical risk. Despite these headwinds, the company’s fundamentals—revenue growth of 19.5%, operating margin of 38.9%, and free cash flow of $171.5 M—remain robust.
Valuation metrics show the market is pricing ADE at a P/E of 27, well below the software industry average of 38, and the DCF‑derived fair value of $43 implies an upside of roughly 24%. The dividend yield of 0.67% with a modest payout ratio of 18% appears sustainable given strong cash generation. However, the balance sheet carries a debt‑to‑equity of 85.8%, which, together with the high beta and volatility, elevates the risk profile. Analyst consensus is a strong‑buy with a median target of $37‑$37.5, reinforcing the upside thesis. In summary, the stock is fundamentally sound and undervalued, yet short‑term technical and risk factors warrant a measured approach.
Valuation metrics show the market is pricing ADE at a P/E of 27, well below the software industry average of 38, and the DCF‑derived fair value of $43 implies an upside of roughly 24%. The dividend yield of 0.67% with a modest payout ratio of 18% appears sustainable given strong cash generation. However, the balance sheet carries a debt‑to‑equity of 85.8%, which, together with the high beta and volatility, elevates the risk profile. Analyst consensus is a strong‑buy with a median target of $37‑$37.5, reinforcing the upside thesis. In summary, the stock is fundamentally sound and undervalued, yet short‑term technical and risk factors warrant a measured approach.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near short‑term support at $26.94
- Bearish MACD signal suggests near‑term downside
- Increasing volume provides downside cushion
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Undervaluation vs DCF fair value of $43
- Strong revenue growth and high operating margins
- Analyst consensus strong‑buy with median target ~$37.5
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Sustainable dividend with low payout ratio
- Robust cash flow and expanding IP licensing franchise
- Long‑term upside of ~24% to fair value despite current volatility
Key Metrics & Analysis
Financial Health
Revenue Growth19.50%
Profit Margin26.50%
P/E Ratio27.4
ROE28.51%
ROA12.67%
Debt/Equity85.81
P/B Ratio7.1
Op. Cash Flow$159.4M
Free Cash Flow$171.5M
Industry P/E38.6
Technical Analysis
TrendBullish
RSI52.0
Support$26.94
Resistance$34.34
MA 20$30.49
MA 50$27.00
MA 200$18.84
MACDBearish
VolumeIncreasing
Fear & Greed Index88.52
Valuation
Fair Value$43.06
Target Price$37.00
Upside/Downside23.83%
GradeUndervalued
TypeBlend
Dividend Yield0.67%
Risk Assessment
Beta2.08
Volatility75.57%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.